BTEE.L vs. EIMI.L
BTEE.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) and EIMI.L (iShares Core MSCI EM IMI UCITS ETF) are both exchange-traded funds - BTEE.L is a Health & Biotech Equities fund tracking the NASDAQ Biotechnology TR USD, while EIMI.L is a Emerging Markets Equities fund tracking the MSCI Emerging Markets Investable Market Index. Both are passively managed. Over the past 5 years, BTEE.L returned 4.70%/yr vs 7.61%/yr for EIMI.L. A 0.50 correlation means they provide meaningful diversification when combined. BTEE.L charges 0.35%/yr vs 0.18%/yr for EIMI.L.
Performance
BTEE.L vs. EIMI.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BTEE.L achieves a 4.58% return, which is significantly lower than EIMI.L's 24.25% return.
BTEE.L
- 1D
- 3.30%
- 1M
- 1.17%
- YTD
- 4.58%
- 6M
- 3.18%
- 1Y
- 41.45%
- 3Y*
- 13.12%
- 5Y*
- 4.70%
- 10Y*
- —
EIMI.L
- 1D
- -1.30%
- 1M
- 4.51%
- YTD
- 24.25%
- 6M
- 27.21%
- 1Y
- 49.41%
- 3Y*
- 23.30%
- 5Y*
- 7.61%
- 10Y*
- 10.26%
BTEE.L vs. EIMI.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 4.58% | 32.82% | -1.69% | 5.84% | -11.88% | -0.57% | 27.55% | 25.56% | -14.84% |
EIMI.L iShares Core MSCI EM IMI UCITS ETF | 24.25% | 32.16% | 7.36% | 11.03% | -19.67% | -0.65% | 18.80% | 16.37% | -16.71% |
Correlation
The correlation between BTEE.L and EIMI.L is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.39 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.44 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.48 |
Correlation (All Time) Calculated using the full available price history since Mar 9, 2018 | 0.50 |
The correlation between BTEE.L and EIMI.L shifts across timeframes, from 0.39 (1 year) to 0.50 (all time), reflecting how their relationship changes across market environments.
BTEE.L vs. EIMI.L - Sectors Allocation Comparison
Sectors
BTEE.L
EIMI.L
Healthcare
Basic Materials
-
Communication Services
-
Consumer Cyclical
-
Consumer Defensive
-
Energy
-
Financial Services
-
Industrials
-
Real Estate
-
Technology
-
Utilities
-
Healthcare
BTEE.L
EIMI.L
Basic Materials
BTEE.L
-
EIMI.L
Communication Services
BTEE.L
-
EIMI.L
Consumer Cyclical
BTEE.L
-
EIMI.L
Consumer Defensive
BTEE.L
-
EIMI.L
Energy
BTEE.L
-
EIMI.L
Financial Services
BTEE.L
-
EIMI.L
Industrials
BTEE.L
-
EIMI.L
Real Estate
BTEE.L
-
EIMI.L
Technology
BTEE.L
-
EIMI.L
Utilities
BTEE.L
-
EIMI.L
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEE.L vs. EIMI.L — Risk / Return Rank
BTEE.L
EIMI.L
BTEE.L vs. EIMI.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) and iShares Core MSCI EM IMI UCITS ETF (EIMI.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BTEE.L | EIMI.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.46 | ||
| Sortino ratioReturn per unit of downside risk | -0.42 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.47 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | 5.41 | 3.88 | +1.52 |
| Martin ratioReturn relative to average drawdown | 16.70 | 14.02 | +2.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BTEE.L | EIMI.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.10 | 2.56 | -0.46 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | 0.42 | -0.19 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.54 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.30 | 0.36 | -0.05 |
Drawdowns
BTEE.L vs. EIMI.L - Drawdown Comparison
The maximum BTEE.L drawdown since its inception was -38.29%, roughly equal to the maximum EIMI.L drawdown of -38.73%. Use the drawdown chart below to compare losses from any high point for BTEE.L and EIMI.L.
Loading charts...
Drawdown Indicators
| BTEE.L | EIMI.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.29% | -38.73% | +0.44% |
Max Drawdown (1Y)Largest decline over 1 year | -7.63% | -12.66% | +5.03% |
Max Drawdown (3Y)Largest decline over 3 years | -26.82% | -17.44% | -9.38% |
Max Drawdown (5Y)Largest decline over 5 years | -38.29% | -35.50% | -2.79% |
Max Drawdown (10Y)Largest decline over 10 years | — | -38.73% | — |
Current DrawdownCurrent decline from peak | -2.58% | -2.64% | +0.06% |
Average DrawdownAverage peak-to-trough decline | -13.56% | -14.04% | +0.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.47% | 3.52% | -1.05% |
Volatility
BTEE.L vs. EIMI.L - Volatility Comparison
The current volatility for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) is 6.84%, while iShares Core MSCI EM IMI UCITS ETF (EIMI.L) has a volatility of 8.18%. This indicates that BTEE.L experiences smaller price fluctuations and is considered to be less risky than EIMI.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEE.L | EIMI.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.84% | 8.18% | -1.34% |
Volatility (6M)Calculated over the trailing 6-month period | 15.33% | 16.71% | -1.38% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.63% | 19.23% | +0.40% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.14% | 18.31% | +2.83% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.50% | 19.15% | +3.35% |
BTEE.L vs. EIMI.L - Expense Ratio Comparison
BTEE.L has a 0.35% expense ratio, which is higher than EIMI.L's 0.18% expense ratio.
Dividends
BTEE.L vs. EIMI.L - Dividend Comparison
BTEE.L's dividend yield for the trailing twelve months is around 0.36%, while EIMI.L has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.36% | 0.37% | 0.46% | 0.39% | 0.44% | 0.25% | 0.17% | 0.14% | 0.07% |
EIMI.L iShares Core MSCI EM IMI UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
BTEE.L and EIMI.L have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, EIMI.L is cheaper at 0.18% per year. The better choice depends on whether you care most about return, fees, risk, or income.
EIMI.L is cheaper with a 0.18% expense ratio, compared with 0.35% for BTEE.L.
BTEE.L is categorized as Health & Biotech Equities, while EIMI.L is Emerging Markets Equities. BTEE.L tracks NASDAQ Biotechnology TR USD, while EIMI.L tracks MSCI Emerging Markets Investable Market Index. Their fees differ too: 0.35% for BTEE.L and 0.18% for EIMI.L.
Find the right allocation for BTEE.L and EIMI.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer